Donate

Be confident. You’re helping find urgent answers to type 1

In 2018, our supporters helped to achieve phenomenal results in type 1 research and advocacy.

These include proof that Professor Hovorka’s artificial pancreas works, successful lab tests for a new rapid-acting and ultra-concentrated insulin and even the potential of using seaweed as part of a cure.

JDRF does not receive any government funding. This means every breakthrough in pioneering type 1 research is only possible because of people like you. Thank you.

Laura, a woman with type 1 diabetes

17-year-old Laura lives with type 1 and has benefited from research breakthroughs such as insulin pumps. Her mum, Lynn, says,

“We would not be where we are today without research and clinical trials. A cure would mean the world to us and it’s our dream. Hope is always in a cure.”

Help us achieve more life-changing breakthroughs in 2019

Right now at the University of Oxford, Professor John Todd is exploring a potential treatment for type 1 that has already delivered results and could one day be used to prevent and cure the condition.

We know that reduced levels of a molecule called IL-2 are linked to the development of type 1 diabetes. Professor Todd’s treatment is based on giving IL-2 to people with type 1. A recent study found IL-2 treatment was safe and boosted ‘good’ immune cells that protect the pancreas.

Now the team wants to understand exactly how this treatment works, whether the drug affects other immune cells and if there are any side-effects. The results of this project will inform future clinical trials of the IL-2 treatment.

Research such as this will impact lives for generations to come. Will you help with a donation today?

By continuing to use the site, you agree to the use of cookies. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close